Английская Википедия:EVT-101

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.[1][2] The drug was first claimed by Roche in 2002.[3] By 2017, EVT-101 was in phase II clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021.[1]

See also

References

Шаблон:Reflist

Шаблон:Ionotropic glutamate receptor modulators


Шаблон:Nervous-system-drug-stub